Compare AbCellera Biologics Inc (ABCL) vs iShares Gold Trust (IAU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

IAU trades at $78.30, up 1.02% with a bearish technical signal from moving averages while oscillators show neutrality. The stock faces resistance near $79 with support at $78. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, though immediate technical indicators suggest caution.

The outlook remains mixed with bullish long-term gold fundamentals supporting IAU, but near-term technical resistance and potential Fed policy shifts pose risks. Investors should weigh strong institutional gold demand against current overbought short-term signals and market volatility.